Pharmacology and laboratory testing of the oral Xa inhibitors

Clinics in Laboratory Medicine

Volumn 34, Issue 3, 2014, Pages 503-517

  Samama, Meyer Michel ^a,b   Meddahi, Sadia ^a,b   Samama, Charles Marc ^a  

^a HÔTEL DIEU   (France)

^b Biomnis Laboratory   (France)

Author keywords

Apixaban; Betrixaban; Bleeding; Edoxaban; Monitoring; Rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; EDOXABAN; ENOXAPARIN; LIXIANA; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; BENZAMIDE DERIVATIVE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLOOD CLOTTING TEST; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; KNEE SURGERY; LABORATORY TEST; LOW DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COMPARATIVE STUDY; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PERSONALIZED MEDICINE; PROCEDURES;

ADMINISTRATION, ORAL; BENZAMIDES; BLOOD COAGULATION TESTS; DRUG MONITORING; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; INDIVIDUALIZED MEDICINE; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES;

EID: 84906938975     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.06.009     Document Type: Review

References (55)

1. Jay McLean (1890-1957), discoverer of heparin. JAMA 1967, 201(10):770.
2. Link K.P. The discovery of dicumarol and its sequels. Circulation 1959, 19:97-107.
3. Weitz J.I., Eikelboom J.W., Samama M.M. American College of Chest Physicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(Suppl 2):e120S-e151S.
4. Samama M.M., Conard J., Flaujac C., et al. Hétérogénéité pharmacologique des nouveaux anticoagulants. JMal Vasc 2011, 36(Suppl 1):S10-S15.
5. Kubitza D., Becka M., Mueck W., et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. JClin Pharmacol 2006, 46:981-990.
6. Ericksson B.I., Rosencher N., Friedman R.J., et al. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip of knee arthroplasty. Thromb Res 2011, 130:147-151.
7. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009, 374:29-38.
8. Halabi A., Kubitza D., Zuehlsdorf M., et al. Effect of hepatic impairment on the pharmacodynamics and tolerability of rivaroxaban - an oral, direct factor Xa inhibitor. JThromb Haemost 2007, 5(Suppl 2):635.
9. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. NEngl J Med 2008, 358:2765-2775.
10. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomised controlled trial. Lancet 2008, 372:31-39.
11. Lassen M.R., Agneo W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. NEngl J Med 2008, 358:2776-2786.
12. Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: a randomised trial. Lancet 2009, 373:1673-1680.
13. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
14. ROCKET AF Study Investigators Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010, 159:340-347.
15. Buller H.R., Lensing A.W., Prins M.H., et al. Adose-ranging study evaluating once daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008, 112:2242-2247.
16. Romualdi E., Donadini M.P., Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (Einstein-extension study). Expert Rev Cardiovasc Ther 2011, 9:841-844.
17. EINSTEIN-PE Investigators, Büller H.R., Prins M.H., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. NEngl J Med 2012, 366:1287-1297.
18. Cohen A.T., Spiro T.E., Spyropoulos A.C. MAGELLAN Steering Committee. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. NEngl J Med 2013, 368:1945-1946.
19. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEngl J Med 2012, 366:9-19.
20. Wang L., Zhang D., Raghavan N., et al. Invitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition and induction studies. Drug Metab Dispos 2009, 38:448-458.
21. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. NEngl J Med 2009, 361:504-604.
22. Lassen M.R., Raskob G.E., Gallus A., ADVANCE-2 Investigators, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010, 375:807-815.
23. Lassen M.R., Gallus A., Raskob G.E., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. NEngl J Med 2010, 363:2487-2498.
24. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation (AVERROES Study). NEngl J Med 2011, 364:806-817.
25. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
26. Agnelli G., Büller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. New Engl J Med 2013, 369:799-808.
27. Agnelli G., Buller H.R., Cohen A., AMPLIFY-EXT Investigators, et al. Apixaban for extended treatment of venous thromboembolism. NEngl J Med 2013, 368:699-708.
28. Levine M.N., Gu C., Liebman H.A., et al. Arandomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. JThromb Haemost 2012, 10:807-814.
29. Goldhaber S.Z., Leizorovicz A., Kakkar A.K., et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. NEngl J Med 2011, 365:2167-2177.
30. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. NEngl J Med 2011, 365:699-708.
31. Camm A.J., Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs 2011, 71:1503-1526.
32. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2013, 369:2093-2104.
33. The Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New Engl J Med 2013, 369:1406-1415.
34. Zhang P., Huang W., Wang L., et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitors. Bioorg Med Chem Lett 2009, 19:2179-2185.
35. Turpie A.G., Bauer K.A., Davidson B.L., et al. Arandomized evaluation of betrixaban an oral factor Xa inhibitor for prevention of thromboembolism events after total knee replacement (EXPERT). Thromb Haemost 2009, 101:68-76.
36. Connolly S.J., Eikelboom J., Dorian P., et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2 randomized dose-ranging study (EXPLORE-Xa). Eur Heart J 2013, 34:1498-1505.
37. Samama M.M., Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011, 49:761-772.
38. Samama M.M., Guinet C., Le Flem L. Deux nouveaux anticoagulants: dabigatran et Rivaroxaban. Leur impact sur les examens de laboratoire. Biotribune 2011, 38:16-21.
39. Gouin-Thibault I., Mismetti P., Flaujac C., et al. Nouveaux anticoagulants par voie orale: quelle place pour les analyses de biologie médicale?. Sang Thrombose Vaisseaux 2011, 23:8-17.
40. Gerotziafas G.T., Baccouche H., Sassi M., et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2012, 129:101-103.
41. Douxfils J., Chatelain C., Chatelain B. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013, 110:283-294.
42. Tripodi A., Chantarangkul V., Guinet C., et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an invitro study. JThromb Haemost 2011, 9:226-228.
43. Samama M.M., Martinoli J.L., Le Flem L., et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
44. Freyburger G., Macouillard G., Labrouche S., et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127:457-465.
45. Samama M.M., Guinet C., Le Flem L., et al. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. JThromb Thrombolysis 2013, 35:140-146.
46. Samama M.M., Contant G., Spiro T.E., et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012, 18:150-158.
47. Samama M.M., Contant G., Spiro T.E., et al. Evaluation of the anti-Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012, 107:379-387.
48. Gouin-Thibault I., Flaujac C., Delavenne X., et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014, 111(2):240-248.
49. Samama M.M., Amiral J., Guinet C., et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010, 104:1078-1079.
50. Pernod G., Elias A., Gouin I., et al. Questions-réponses sur l'utilisation du rivaroxaban dans le traitement de la maladie thromboembolique veineuse. JMal Vasc 2012, 37:300-310.
51. Rohatagi S., Mendell J., Kastrissios H., et al. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. Thromb Haemost 2012, 108:887-895.
52. Sié P., Samama C.M., Godier A., et al. Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors. Ann Fr Anesth Reanim 2011, 30:645-650.
53. Samama M.M., Conard J., Lillo-Le Louët A. Accidents hémorragiques des nouveaux anticoagulants. JMal Vasc 2013, 38:259-270.
54. Mirdamadi A. Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia. ARYA Atheroscler 2013, 9:112-114.
55. Bhatt V.R., Aryal M.R., Armitage J.O. Nonheparin anticoagulants for heparin-induced thrombocytopenia. NEngl J Med 2013, 368:2333-2334.